FDA Medical Device Exemptions for Low-Risk Unclassified Products

The FDA Medical Device Exemptions target specific unclassified preamendment devices that present minimal risk to patients. By exercising enforcement discretion, the agency no longer expects manufacturers to submit 510(k) premarket notification applications for these products until a formal exemption is issued or new safety information emerges.

Legislative Drive for Burden Reduction

These FDA Medical Device Exemptions stem from commitments made during the reauthorization of the Medical Device User Fee Amendments and Section 3054 of the 21st Century Cures Act. The policy maintains all other statutory requirements, including registration, labeling, quality system regulations, and adverse-event reporting, while explicitly excluding combination products.

Specialty Distribution of Exempted Codes

The June 2026 FDA update adds five new devices to the existing list, producing a targeted collection across eight clinical panels. Ear, nose, and throat devices represent the largest share, with additional entries in gastroenterology-urology, general and plastic surgery, obstetrics and gynecology, physical medicine, neurology, toxicology, and ophthalmology.

As detailed in the FDA’s intent to exempt certain unclassified medical devices, the following product codes now qualify:

Accelerated Pathways and Post-Market Focus

Manufacturers benefit from faster market entry and lower premarket costs under these FDA Medical Device Exemptions. Health economic evaluations can therefore shift resources toward real-world evidence and ongoing surveillance rather than premarket dossiers, while safety oversight remains intact through existing quality and reporting systems.